AU2019321424B2 - Pyrrolo(1,2-b)pyridazine derivatives as IRAK4 inhibitors - Google Patents

Pyrrolo(1,2-b)pyridazine derivatives as IRAK4 inhibitors Download PDF

Info

Publication number
AU2019321424B2
AU2019321424B2 AU2019321424A AU2019321424A AU2019321424B2 AU 2019321424 B2 AU2019321424 B2 AU 2019321424B2 AU 2019321424 A AU2019321424 A AU 2019321424A AU 2019321424 A AU2019321424 A AU 2019321424A AU 2019321424 B2 AU2019321424 B2 AU 2019321424B2
Authority
AU
Australia
Prior art keywords
alkyl
inhibitors
nhc
cycloalkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019321424A
Other languages
English (en)
Other versions
AU2019321424A1 (en
Inventor
Stephen AMMANN
Elizabeth M. Bacon
Gediminas BRIZGYS
Elbert Chin
Chienhung CHOU
Jeromy J. Cottell
Marilyn NDUKWE
James G. Taylor
Nathan E. Wright
Zheng-Yu Yang
Sheila M. Zipfel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU2019321424A1 publication Critical patent/AU2019321424A1/en
Priority to AU2022204399A priority Critical patent/AU2022204399A1/en
Application granted granted Critical
Publication of AU2019321424B2 publication Critical patent/AU2019321424B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AU2019321424A 2018-08-13 2019-08-13 Pyrrolo(1,2-b)pyridazine derivatives as IRAK4 inhibitors Active AU2019321424B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022204399A AU2022204399A1 (en) 2018-08-13 2022-06-22 Pyrrolo[1,2-B]pyridazine derivatives as IRAK4 inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862718273P 2018-08-13 2018-08-13
US62/718,273 2018-08-13
PCT/US2019/046380 WO2020036979A1 (en) 2018-08-13 2019-08-13 Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022204399A Division AU2022204399A1 (en) 2018-08-13 2022-06-22 Pyrrolo[1,2-B]pyridazine derivatives as IRAK4 inhibitors

Publications (2)

Publication Number Publication Date
AU2019321424A1 AU2019321424A1 (en) 2021-01-28
AU2019321424B2 true AU2019321424B2 (en) 2022-07-14

Family

ID=67777432

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019321424A Active AU2019321424B2 (en) 2018-08-13 2019-08-13 Pyrrolo(1,2-b)pyridazine derivatives as IRAK4 inhibitors
AU2022204399A Abandoned AU2022204399A1 (en) 2018-08-13 2022-06-22 Pyrrolo[1,2-B]pyridazine derivatives as IRAK4 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022204399A Abandoned AU2022204399A1 (en) 2018-08-13 2022-06-22 Pyrrolo[1,2-B]pyridazine derivatives as IRAK4 inhibitors

Country Status (9)

Country Link
US (1) US11572362B2 (cg-RX-API-DMAC7.html)
EP (1) EP3837012A1 (cg-RX-API-DMAC7.html)
JP (2) JP7169429B2 (cg-RX-API-DMAC7.html)
KR (1) KR102660255B1 (cg-RX-API-DMAC7.html)
CN (1) CN112566697B (cg-RX-API-DMAC7.html)
AU (2) AU2019321424B2 (cg-RX-API-DMAC7.html)
CA (1) CA3105795C (cg-RX-API-DMAC7.html)
TW (1) TWI797366B (cg-RX-API-DMAC7.html)
WO (1) WO2020036979A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022007376A (es) 2019-12-20 2022-09-02 Tenaya Therapeutics Inc Fluoroalqull-oxadiazoles y sus usos.
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210036A1 (en) * 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
WO2018152368A1 (en) * 2017-02-16 2018-08-23 Gilead Sciences, Inc. Pyrrolo [1,2-b] pyridazine derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3126330T3 (en) 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
US9624246B2 (en) 2015-02-06 2017-04-18 Merck Patent Gmbh Pyridazinone macrocycles as IRAK inhibitors and uses thereof
EP3313840B1 (en) 2015-06-24 2019-07-24 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
ES2822956T3 (es) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210036A1 (en) * 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
WO2018152368A1 (en) * 2017-02-16 2018-08-23 Gilead Sciences, Inc. Pyrrolo [1,2-b] pyridazine derivatives

Also Published As

Publication number Publication date
CA3105795A1 (en) 2020-02-20
CA3105795C (en) 2024-01-16
EP3837012A1 (en) 2021-06-23
TWI797366B (zh) 2023-04-01
US20200071333A1 (en) 2020-03-05
JP7169429B2 (ja) 2022-11-10
AU2022204399A1 (en) 2022-07-14
WO2020036979A1 (en) 2020-02-20
KR20210044819A (ko) 2021-04-23
TW202021966A (zh) 2020-06-16
CN112566697B (zh) 2024-04-16
CN112566697A (zh) 2021-03-26
JP2022130716A (ja) 2022-09-06
JP2021535904A (ja) 2021-12-23
KR102660255B1 (ko) 2024-04-25
AU2019321424A1 (en) 2021-01-28
US11572362B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
TWI733982B (zh) 吡咯并[1,2-b]嗒衍生物
JP7216189B2 (ja) チアジアゾールｉｒａｋ４阻害剤
AU2022204399A1 (en) Pyrrolo[1,2-B]pyridazine derivatives as IRAK4 inhibitors
AU2022252741A1 (en) Pyrrolo[1,2-b]pyridazine derivatives as IRAK4 inhibitors
HK40045601A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
HK40045605A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
HK40019121A (en) Pyrrolo [1,2-b]pyridazine derivatives
HK40019121B (en) Pyrrolo [1,2-b]pyridazine derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)